Donepezil

• Description:

  Donepezil (E2020 free base) is a specific and potent AChE inhibitor with IC50s of 8.12 nM and 11.6 nM for bovine AChE and human AChE, respectively[1].

• Product Name Alternative:

  E2020 (free base)

• UNSPSC:

  12352005

• Hazard Statement:

  H300

• Target:

  Cholinesterase (ChE)

• Type:

  Reference compound

• Related Pathways:

  Neuronal Signaling

• Applications:

  Neuroscience-Neuromodulation

• Field of Research:

  Neurological Disease; Cancer

• Assay Protocol:

  https://www.medchemexpress.com/donepezil.html

• Purity:

  99.91

• Solubility:

  DMSO : 33.33 mg/mL (ultrasonic)

• Smiles:

  O=C(C(C=C(OC)C(OC)=C1)=C1C2)C2CC(CC3)CCN3CC4=CC=CC=C4

• Molecular Formula:

  C24H29NO3

• Molecular Weight:

  379.49

• Precautions:

  H300

• References & Citations:

  [1]Ogura, H., et al., Comparison of inhibitory activities of donepezil and other cholinesterase inhibitors on acetylcholinesterase and butyrylcholinesterase in vitro. Methods Find Exp Clin Pharmacol, 2000. 22 (8) : p. 609-13.|[2]Snape, M.F., et al., A comparative study in rats of the in vitro and in vivo pharmacology of the acetylcholinesterase inhibitors tacrine, donepezil and NXX-066. Neuropharmacology, 1999. 38 (1) : p. 181-93.|[3]Huang, Z.H., et al., Donepezil protects endothelial cells against hydrogen peroxide-induced cell injury. CNS Neurosci Ther, 2012. 18 (2) : p. 185-7.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  4°C (Powder, sealed storage, away from moisture and light)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Launched

• Isoform:

  AChE

• Citation 01:

  BioRxiv. 2024 Dec 23:2024.12.22.629999.|Chem Biodivers. 2025 Jan 7:e202402771.|Comput Struct Biotechnol J. 2023 Feb 24:21:1907-1920.|Eur J Med Chem. 2024 Feb 5:265:116071.|Foods. 2022 Jul 14;11 (14) :2095.|Foods. 2025 May 29;14 (11) :1938.|Int Immunopharmacol. 2025 Mar 19:153:114442.|Int J Mol Sci. 2025 Apr 17;26 (8) :3781.|J Ethnopharmacol. 2024 Nov 9;338 (Pt 1) :119017.|J Ethnopharmacol. 2025 Apr 9:345:119619.|Journal of Pharmaceutical Investigation. 2021 Mar 31.|Mol Brain. 2025 Apr 4;18 (1) :29.|Phytomedicine. 2024 Jun 4:131:155802.|Alzheimers Res Ther. 2025 Feb 14;17 (1) :43.|Cancer Cell. 2025 Aug 12:S1535-6108 (25) 00330-7.|Clin Transl Med. 2021 Jun;11 (6) :e428.|Food Biosci. 2025 Sep.|J Integr Neurosci. 2023 May 16;22 (3) :76.|Neurol Res. 2025 Sep 13:1-18.|Patent. US20210378961A1.|Research Square Preprint. 2024 Apr 23.

• CAS Number:

  [120014-06-4]